About Us

Prior Transave Announcements

Transave Announces Positive Phase II Results for Once Daily Arikace™ in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections

June 13, 2008

Study Confirms Anti-infective Arikace™ Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients

March 31, 2008

Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing

March 31, 2008

Transave, Inc Announces Appointment of Nicholas Gurreri as Senior Vice President of Commercial Operations and Business Development

June 26, 2007

Transave, Inc. Appoints Mich Soga as Chief Financial Officer

May 11, 2007

Transave, Inc. Appoints Renu Gupta, M.D. Chief Medical Officer

October 2, 2006

Transave’s Slit™ Amikacin is Granted Orphan Drug Designation by the European Commision for the Treatment of Pseudonomas Aerugonisoa Lung Infections in Cystic Fibrosis

August 2, 2006

Transave, Inc. Appoints Timothy G. Whitten President and Chief Executive Officer

June 19, 2006

Transave, Inc. Appoints Donald Hayden, Jr. Executive Chairman of its Board of Directors

April 28, 2006

Transave Receives Orphan Drug Designation from the FDA for SLIT™ Amikacin for Treatment of Pulmanary Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

March 26, 2006

Press Releases

May. 16, 2012
Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman Read More
May. 8, 2012
Insmed Announces First Quarter 2012 Financial Results Read More